JP6883904B2 - 線維芽細胞の製造方法及びg−csf陽性線維芽細胞集団 - Google Patents
線維芽細胞の製造方法及びg−csf陽性線維芽細胞集団 Download PDFInfo
- Publication number
- JP6883904B2 JP6883904B2 JP2020539572A JP2020539572A JP6883904B2 JP 6883904 B2 JP6883904 B2 JP 6883904B2 JP 2020539572 A JP2020539572 A JP 2020539572A JP 2020539572 A JP2020539572 A JP 2020539572A JP 6883904 B2 JP6883904 B2 JP 6883904B2
- Authority
- JP
- Japan
- Prior art keywords
- fibroblasts
- positive
- cells
- hcf
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70542—CD106
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Vascular Medicine (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021076105A JP7428389B2 (ja) | 2018-08-29 | 2021-04-28 | 線維芽細胞の製造方法及びg-csf陽性線維芽細胞集団 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018160898 | 2018-08-29 | ||
| JP2018160898 | 2018-08-29 | ||
| PCT/JP2019/033835 WO2020045547A1 (ja) | 2018-08-29 | 2019-08-29 | 線維芽細胞の製造方法及びg-csf陽性線維芽細胞集団 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021076105A Division JP7428389B2 (ja) | 2018-08-29 | 2021-04-28 | 線維芽細胞の製造方法及びg-csf陽性線維芽細胞集団 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2020045547A1 JPWO2020045547A1 (ja) | 2021-02-15 |
| JP6883904B2 true JP6883904B2 (ja) | 2021-06-09 |
Family
ID=69642802
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539572A Active JP6883904B2 (ja) | 2018-08-29 | 2019-08-29 | 線維芽細胞の製造方法及びg−csf陽性線維芽細胞集団 |
| JP2021076105A Active JP7428389B2 (ja) | 2018-08-29 | 2021-04-28 | 線維芽細胞の製造方法及びg-csf陽性線維芽細胞集団 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021076105A Active JP7428389B2 (ja) | 2018-08-29 | 2021-04-28 | 線維芽細胞の製造方法及びg-csf陽性線維芽細胞集団 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210254009A1 (https=) |
| EP (1) | EP3845635A4 (https=) |
| JP (2) | JP6883904B2 (https=) |
| KR (1) | KR102883773B1 (https=) |
| CN (1) | CN112639082A (https=) |
| AU (1) | AU2019332400B2 (https=) |
| CA (1) | CA3110831A1 (https=) |
| IL (1) | IL281081B (https=) |
| SG (1) | SG11202102028SA (https=) |
| WO (1) | WO2020045547A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021118728A (ja) * | 2018-08-29 | 2021-08-12 | 株式会社メトセラ | 線維芽細胞の製造方法及びg−csf陽性線維芽細胞集団 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021177387A1 (ja) * | 2020-03-04 | 2021-09-10 | 株式会社メトセラ | エリスロポエチン産生能が亢進された線維芽細胞 |
| CA3211113A1 (en) | 2021-03-04 | 2022-09-09 | Metcela Inc. | Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same |
| US20240316113A1 (en) | 2021-09-08 | 2024-09-26 | Metcela Inc. | Fibroblast-containing pharmaceutical composition for treating kidney disease |
| CN119685401A (zh) * | 2024-06-03 | 2025-03-25 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种改造成纤维细胞的方法及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1886150B (zh) * | 2003-10-27 | 2010-05-26 | 学校法人庆应义塾 | 含有g-csf的成纤维细胞动员剂及创伤治疗剂 |
| US9987310B2 (en) * | 2013-11-27 | 2018-06-05 | University Of Louisville Research Foundation, Inc. | Cardiac progenitor cells and methods of use therefor |
| CN106661552B (zh) * | 2014-07-11 | 2020-07-07 | 玛土撤拉有限公司 | 心脏细胞培养材料 |
| CN107881145A (zh) * | 2016-09-26 | 2018-04-06 | 新乡医学院 | 一种分选大鼠心成纤维细胞cd90+亚群的方法及其应用 |
| KR102407387B1 (ko) * | 2017-02-24 | 2022-06-10 | 가부시키가이샤 메토세라 | 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법 |
| EP3845635A4 (en) * | 2018-08-29 | 2022-06-15 | Metcela Inc. | PROCEDURE FOR PREPARING FIBROBLAST AND G-CSF-POSITIVE FIBROBLAST MASS |
-
2019
- 2019-08-29 EP EP19856084.9A patent/EP3845635A4/en active Pending
- 2019-08-29 CN CN201980056534.7A patent/CN112639082A/zh active Pending
- 2019-08-29 AU AU2019332400A patent/AU2019332400B2/en active Active
- 2019-08-29 CA CA3110831A patent/CA3110831A1/en active Pending
- 2019-08-29 JP JP2020539572A patent/JP6883904B2/ja active Active
- 2019-08-29 IL IL281081A patent/IL281081B/en unknown
- 2019-08-29 WO PCT/JP2019/033835 patent/WO2020045547A1/ja not_active Ceased
- 2019-08-29 SG SG11202102028SA patent/SG11202102028SA/en unknown
- 2019-08-29 KR KR1020217009135A patent/KR102883773B1/ko active Active
-
2021
- 2021-02-26 US US17/187,459 patent/US20210254009A1/en active Pending
- 2021-04-28 JP JP2021076105A patent/JP7428389B2/ja active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021118728A (ja) * | 2018-08-29 | 2021-08-12 | 株式会社メトセラ | 線維芽細胞の製造方法及びg−csf陽性線維芽細胞集団 |
| JP7428389B2 (ja) | 2018-08-29 | 2024-02-06 | 株式会社メトセラ | 線維芽細胞の製造方法及びg-csf陽性線維芽細胞集団 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3845635A4 (en) | 2022-06-15 |
| IL281081A (en) | 2021-04-29 |
| CA3110831A1 (en) | 2020-03-05 |
| IL281081B (en) | 2022-07-01 |
| AU2019332400A1 (en) | 2021-04-01 |
| SG11202102028SA (en) | 2021-03-30 |
| JP2021118728A (ja) | 2021-08-12 |
| KR20210049892A (ko) | 2021-05-06 |
| EP3845635A1 (en) | 2021-07-07 |
| WO2020045547A1 (ja) | 2020-03-05 |
| KR102883773B1 (ko) | 2025-11-07 |
| AU2019332400B2 (en) | 2025-06-26 |
| CN112639082A (zh) | 2021-04-09 |
| JP7428389B2 (ja) | 2024-02-06 |
| JPWO2020045547A1 (ja) | 2021-02-15 |
| US20210254009A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6883904B2 (ja) | 線維芽細胞の製造方法及びg−csf陽性線維芽細胞集団 | |
| US20230149469A1 (en) | Wound healing and tissue engineering | |
| JP7072135B2 (ja) | 線維芽細胞を含む心臓疾患を治療するための注射用組成物、及び治療用線維芽細胞の製造方法 | |
| EP1099754A1 (en) | Mesenchymal stem cells and/or progenitor cells, their isolation and use | |
| CN113574167B (zh) | 利用混合物4f增加干细胞生物学活性的组合物 | |
| KR20180130625A (ko) | 인간 성체 간세포 리프로그래밍 배지 조성물 | |
| JP6766082B2 (ja) | 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途 | |
| US20130251691A1 (en) | Embryonic Stem Cell-Derived Cardiomyocytes and a Cellular Therapeutic Agent Comprising the Same as an Active Ingredient | |
| JP2018530992A6 (ja) | 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途 | |
| KR20120041212A (ko) | 심장 조직-유래 세포 | |
| JP7233147B2 (ja) | リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 | |
| JP2023053044A (ja) | エリスロポエチン産生能が亢進された線維芽細胞 | |
| RU2800644C2 (ru) | Способ получения фибробластов и г-ксф-положительная фибробластная масса | |
| CN117120063A (zh) | 淋巴管新生促进因子表达成纤维细胞以及含有该细胞的医药组合物 | |
| JP2017222581A (ja) | 肝臓組織再生用組成物 | |
| WO2024176514A1 (ja) | 心臓内幹細胞を含む細胞集団 | |
| CN121136915A (zh) | 富含蛋白酶体人胎盘源促血管干细胞外囊泡分离及其应用 | |
| WO2013010406A1 (zh) | Rna胞体及其用途 | |
| Nadworny | Examining The Role Of Redox Biology In A Population Of Neonatal Cardiac Precursor Cells Marked By The Type Iii Receptor Tyrosine Kinase, C-Kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200804 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200804 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200804 |
|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20200818 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201008 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20201119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210406 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210428 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6883904 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |